TY - JOUR
T1 - Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
T2 - A retrospective analysis by the adult acute myeloid leukemia working group of the Japan society for hematopoietic cell transplantation
AU - Takami, Akiyoshi
AU - Yano, Shingo
AU - Yokoyama, Hiroki
AU - Kuwatsuka, Yachiyo
AU - Yamaguchi, Takuhiro
AU - Kanda, Yoshinobu
AU - Morishima, Yasuo
AU - Fukuda, Takahiro
AU - Miyazaki, Yasushi
AU - Nakamae, Hirohisa
AU - Tanaka, Junji
AU - Atsuta, Yoshiko
AU - Kanamori, Heiwa
N1 - Funding Information:
Financial disclosure statement: This study was supported by grants from the Ministry of Health, Labour, and Welfare of Japan, the Ministry of Education, Culture, Sports and Technology of Japan. This work was supported in part by a Research on Allergic Disease and Immunology ( H23-010 ) in Health and Labor Science Grant from the Ministry of Health, Labour, and Welfare of Japan. The funders played no role in the study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.
Publisher Copyright:
© 2014 American Society for Blood and Marrow Transplantation.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Because the efficacy of donor lymphocyte infusion (DLI) for acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains uncertain, especially in the Asian population, a nationwide registry study was retrospectively performed by the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation to identify the factors affecting the patient survival after DLI. Among 143 adult AML patients who received DLI for the treatment of first hematological relapse after HSCT, the overall survival rates at 1year, 2years, and 5years were 32%±4%, 17%±3%, and 7%±3%, respectively. Complete remission (CR) at the time of DLI, which was obtained in 8% of the patients, was the strongest predictive factor for survival after DLI. Therefore, long-term survival after DLI was achieved almost exclusively in patients who successfully achieved a CR before DLI, indicating the limited efficacy of DLI in a minority of patients.
AB - Because the efficacy of donor lymphocyte infusion (DLI) for acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains uncertain, especially in the Asian population, a nationwide registry study was retrospectively performed by the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation to identify the factors affecting the patient survival after DLI. Among 143 adult AML patients who received DLI for the treatment of first hematological relapse after HSCT, the overall survival rates at 1year, 2years, and 5years were 32%±4%, 17%±3%, and 7%±3%, respectively. Complete remission (CR) at the time of DLI, which was obtained in 8% of the patients, was the strongest predictive factor for survival after DLI. Therefore, long-term survival after DLI was achieved almost exclusively in patients who successfully achieved a CR before DLI, indicating the limited efficacy of DLI in a minority of patients.
KW - Acute myeloid leukemia
KW - Complete remission
KW - Donor lymphocyte infusion
UR - http://www.scopus.com/inward/record.url?scp=84908080603&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908080603&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2014.07.010
DO - 10.1016/j.bbmt.2014.07.010
M3 - Article
C2 - 25034960
AN - SCOPUS:84908080603
SN - 1083-8791
VL - 20
SP - 1785
EP - 1790
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 11
ER -